Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024

ARVN 10.21.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-10-30
Name of Upcoming Event:not specified
Full Press ReleaseSEC FilingsOur ARVN Tweets

About Gravity Analytica

Recent News

  • 01.10.2025 - Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update
  • 12.10.2024 - Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
  • 12.10.2024 - Jeet Mukherjee

Recent Filings

  • 01.22.2025 - 8-K Current report
  • 01.10.2025 - EX-99.1 EX-99.1

NEW HAVEN, Conn., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review third quarter 2024 financial results and provide a corporate update during a live webcast on Wednesday, October 30, 2024, at 8:00 a.m. ET.

The webcast can be accessed under “Events and Presentations” on theinvestor pageof the Arvinas website. A replay of the webcast will be available on theArvinas websitefollowing the completion of the event.

About ArvinasArvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC®(PROteolysis Targeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect onLinkedInandX.

ContactsInvestors:Jeff Boyle+1 (347) 247-5089Jeff.Boyle@arvinas.com

Media:Kirsten Owens+1 (203) 584-0307Kirsten.Owens@arvinas.com

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com